#23 - Tom Dayspring, M.D., FACP, FNLA – Part IV of V: Statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain

Episode Summary

Executive Summary: This episode is a deep dive into lipid-lowering therapies, tracing the evolution from early cholesterol drugs to statins, ezetimibe, fibrates, niacin, and PCSK9 inhibitors. The discussion emphasizes that clinical benefit depends less on changing a biomarker and more on how a drug alters ApoB/LDL clearance, while also warning against overreliance on surrogate endpoints, CK/LFT monitoring, and one-size-fits-all statin use.

Main Topics: Evolution of cholesterol-lowering drugs (Priority: 5/5): The conversation reviews early agents (niacin, neomycin, bile acid sequestrants, triparanol) and how statins became the first broadly successful LDL-lowering class with outcome data. Statins, LDL receptors, and outcome evidence (Priority: 5/5): Statins are framed as the foundational therapy because they lower LDL by increasing LDL receptor expression and have strong clinical outcome data, despite limitations in trial duration and concerns about side effects. Ezetimibe (Zetia) mechanism and trial interpretation (Priority: 4/5): Ezetimibe is discussed as a cholesterol-absorption inhibitor that also affects biliary cholesterol handling; the speakers argue its early trials were poorly designed because they relied on IMT rather than hard outcomes. Fibrates and triglyceride-rich lipoproteins (Priority: 4/5): Fibrates are presented as useful mainly in hypertriglyceridemic, insulin-resistant patients, with evidence for event reduction and possible microvascular benefits in selected populations. Niacin’s decline in favor (Priority: 4/5): Niacin is criticized as a toxic, outdated therapy whose trials failed to show meaningful outcome benefit despite improving HDL-C and ApoB in some settings. PCSK9 inhibitors as a modern breakthrough (Priority: 5/5): PCSK9 inhibitors are highlighted as a remarkable proof that further LDL/ApoB lowering on top of statins can still reduce events, even in already-treated high-risk patients. Brain health, statins, and desmosterol (Priority: 5/5): A nuanced debate explores whether excessive cholesterol synthesis suppression may affect brain cholesterol metabolism and cognition in a subset of patients, with desmosterol proposed as a biomarker.

Key Arguments: Clinical benefit tracks best with therapies that enhance LDL receptor-mediated clearance of ApoB particles, not merely those that improve a lipid biomarker. Statins succeeded because they inhibit cholesterol synthesis high in the pathway and upregulate LDL receptors without broadly disrupting other pathways. Ezetimibe was unfairly dismissed because early trials used surrogate endpoints like carotid IMT instead of hard cardiovascular outcomes. Fibrates appear most useful in patients with elevated triglycerides, low HDL, insulin resistance, and residual ApoB-rich lipoproteins. Niacin lowered ApoB and raised HDL-C, but outcome trials failed and toxicity/insulin resistance likely offset any lipid benefit. PCSK9 inhibitors validated the concept that even modest additional LDL lowering on top of statins can reduce events in very high-risk patients. CK and routine LFT monitoring are poor tools for judging statin toxicity or response; symptoms and individualized assessment matter more. Brain cholesterol synthesis may be relevant to cognition in a subset of patients, and desmosterol may help identify those at risk from excessive statin effect.

Data Points: Statin trial duration: ~5 years - Early outcome trials were relatively short compared with the decades-long development of atherosclerosis. 4S simvastatin trial: 25% reduction in clinical events - Secondary prevention in post-MI Swedish men with very high LDL/FH phenotype. West of Scotland / primary prevention statin trials: NNT in the 40s to 50s - Primary prevention FH-like populations had good but less dramatic absolute benefit. Triparanol approval window: Pulled in the late 1960s, ~3-4 years after approval - Lowered cholesterol but caused cataracts, atherosclerosis, and other harms. AIM-HIGH / niacin effect: Further ApoB lowering without outcome benefit - Niacin added to statin-based therapy improved lipids but did not reduce events. Coronary Drug Project niacin dose: 4 grams/day - Immediate-release niacin was used at pharmacologic doses, not vitamin doses. HATS trial size: ~98-100 subjects - Small angiographic niacin study with crossover-like baseline/follow-up interpretation. PCSK9 inhibitor FOURIER baseline LDL-C: 92 mg/dL average - Patients were already on statins and still benefited from additional LDL lowering. PCSK9 inhibitor trial duration: <2.5 years - Despite short follow-up, event reduction was still observed. Desmosterol cutoff: <0.5 - Proposed threshold associated with impaired cholesterol synthesis and cognitive risk in biomarker studies. ROC/AUC for desmosterol biomarker: ~0.8 to 0.87 - Suggested strong predictive value for identifying low cholesterol synthesis states. Statin-related diabetes risk: Small subset / slight uptick - Acknowledged as real but not a reason to broadly avoid statins. Statin muscle toxicity monitoring: CK elevation up to 10,000-fold - Speaker argues CK is not useful unless extremely elevated or symptoms are present.

Pivotal Quotes: "the only drugs that have ever shown to both reduce cholesterol, but more importantly, reduce events, have either been in isolation or in compounds or in combination, where they are enhancing clearance" — Tom Dayspring: Summarizing the core mechanism behind successful lipid-lowering therapies. "you've got to think of every drug like you think of a tool" — Peter Attia: Explaining individualized prescribing and the importance of knowing each drug’s limitations. "I would make the case that if I wanted a lipid-lowering drug in the drinking water is first line, it would be ezetimibe, not a statin" — Tom Dayspring: A provocative argument that ezetimibe may be the most physiologically elegant first-line agent.

Implications: Listeners should think in terms of ApoB clearance, patient phenotype, and trial design—not just LDL-C or HDL-C. The episode argues for individualized lipid therapy, more thoughtful biomarker use, and continued openness to combination treatment and newer agents.